December 19th 2024
Using Orexo’s powder-based drug delivery technology, the companies will develop mucosal vaccines in an inhaled formulation.
December 12th 2024
The companies will develop a platform that can enable rapid development of DPI products.
December 3rd 2024
Lonza’s new tailored offering leverages the company’s bi-layer capsule manufacturing technology.
November 20th 2024
Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.
October 10th 2024
Solving the challenge of better-stabilized temperature-sensitive biomolecules hinges on innovative formulation strategies.